VENLAFAXINE APPL XR venlafaxine (as hydrochloride) 75 mg modified release capsule blister pack

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

venlafaxine hydrochloride, Quantity: 84.9 mg (Equivalent: venlafaxine, Qty 75 mg)

Disponível em:

Alembic Pharmaceuticals Australia Pty Ltd

DCI (Denominação Comum Internacional):

Venlafaxine hydrochloride

Forma farmacêutica:

Capsule, modified release

Composição:

Excipient Ingredients: iron oxide black; colloidal anhydrous silica; ethylcellulose; iron oxide red; magnesium stearate; microcrystalline cellulose; povidone; purified talc; titanium dioxide; Gelatin; copovidone; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; Shellac; ethanol absolute; ammonia

Via de administração:

Oral

Unidades em pacote:

28 capsules

Tipo de prescrição:

(S4) Prescription Only Medicine

Indicações terapêuticas:

VENLAFAXINE APPL XR is indicated for the treatment of: - Major depression, including prevention of relapse and recurrence where appropriate; - Generalised anxiety disorder; - Social anxiety disorder; Panic disorder, including prevention of relapse.

Resumo do produto:

Visual Identification: Peach opaque cap/ peach opaque body, size 1 hard capsule with thick and thin radial circular bands on both the cap and body in red ink.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Status de autorização:

Licence status A

Data de autorização:

2017-05-17